The UHRF1BP1 antibody is a research tool designed to detect UHRF1BP1 (Ubiquitin-like with PHD and RING Finger Domains 1 Binding Protein 1), a protein implicated in epigenetic regulation and chromatin remodeling. UHRF1BP1 interacts with UHRF1. a key player in maintaining DNA methylation patterns during replication, suggesting its role in bridging DNA repair, cell cycle control, and epigenetic stability. This protein is broadly expressed in tissues and is linked to cellular processes such as apoptosis, DNA damage response, and transcriptional regulation.
Antibodies targeting UHRF1BP1 are commonly used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to study its expression, localization, and interactions. Research highlights its dysregulation in cancers, including breast and colorectal cancer, where altered UHRF1BP1 levels correlate with tumor progression and poor prognosis. Studies also explore its involvement in neurodevelopmental disorders and autoimmune diseases, though mechanisms remain under investigation.
Commercial UHRF1BP1 antibodies are typically validated for specificity using knockout controls or siRNA knockdowns. Challenges include cross-reactivity due to structural similarities with other ubiquitin-like proteins, necessitating careful validation for experimental accuracy. Current research focuses on elucidating UHRF1BP1’s role in UHRF1-mediated epigenetic pathways and its potential as a therapeutic target. This antibody remains vital for advancing understanding of epigenetic dysregulation in disease contexts.